<DOC>
	<DOC>NCT01433263</DOC>
	<brief_summary>A safety &amp; efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas</brief_summary>
	<brief_title>Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Antibodies, Blocking</mesh_term>
	<criteria>Key Inclusion criteria: 1. Patients must sign an informed consent before assessment 2. Patients with pathologically and/or clinically confirmed diagnosis of stage IV nonsmall (squamous or nonsquamous) cell lung cancer (NSCLC) or stage III/IV adenocarcinoma of the pancreas. 3. Patients with stage IV NSCLC will be receiving or completed or discontinued standard chemotherapy or be chemotherapynaive by choice. 4. Patients with stage III/IV pancreatic adenocarcinoma will be receiving standard chemotherapy or no chemotherapy. If patients are receiving chemotherapy, a change in chemotherapy is not expected. 5. Greater than or equal to 5% unintentional weight loss over the previous 36 months, not explained by simple starvation. Simple starvation is considered to be excluded when weight loss is not ameliorated by standard nutritional counseling and oral supplementation over a 2 week period. 6. Body mass index (BMI) â‰¤ 30 kg/m2. 7. Life expectancy of at least 4 months. 8. Able to communicate well and comply with the requirements of the study, including by phone and written logs. Key Exclusion criteria: 1. Patients who have received investigational antineoplastic therapy within 3 weeks of screening 2. Evidence of inadequate organ or brain function, as defined by lab tests and imaging 3. Patients with severe and/or uncontrolled medical conditions that could interfere with the study (e.g. heart conditions, high blood pressure, diabetes, infection) uncontrolled pain or any other nonstable illness 4. Pregnant or lactating women. 5. Women capable of becoming pregnant must use highly effective contraception during the study and for 8 weeks after stopping treatment. All female patients must have negative pregnancy test results throughout the study 6. Patients unwilling or unable to follow instructions. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Wasting syndrome</keyword>
	<keyword>emaciation</keyword>
	<keyword>lung cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>